LIVN

SEC source: 0001639691-25-000078 · wk-form4_1750193643.xml · derivative · entry 4

Enxing Seng Stacy · CIK 0001329921 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,042

Underlying: Ordinary Shares · 4,042 shares

Expires not disclosed

F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Company's 2025 Director Incentive Award Plan (the 2025 Plan) and the 2025 Plan award agreement.

F6 · derivative.exercise_date: The RSUs, granted under the 2025 Plan, vest on June 15, 2026, subject to continued service during the vesting period and the terms of the 2025 Plan award agreement.

F6 · derivative.expiration_date: The RSUs, granted under the 2025 Plan, vest on June 15, 2026, subject to continued service during the vesting period and the terms of the 2025 Plan award agreement.

SEC source: 0001639691-25-000078 · wk-form4_1750193643.xml · derivative · entry 3

Enxing Seng Stacy · CIK 0001329921 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 3,416 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Company's 2015 Incentive Award Plan (the 2015 Plan) and the 2015 Plan award agreement.

F4 · derivative.exercise_date: RSUs granted under the 2015 Plan on June 15, 2024 that vested on June 15, 2025.

F4 · derivative.expiration_date: RSUs granted under the 2015 Plan on June 15, 2024 that vested on June 15, 2025.

SEC source: 0001639691-25-000078 · wk-form4_1750193643.xml · nonDerivative · entry 2

Enxing Seng Stacy · CIK 0001329921 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,751

F3 · shares: Shares withheld to satisfy tax liability.

SEC source: 0001639691-25-000078 · wk-form4_1750193643.xml · nonDerivative · entry 1

Enxing Seng Stacy · CIK 0001329921 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,161

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Reporting person had vested restricted stock units (RSUs) settled in ordinary shares of LivaNova PLC (the Company), 1.00 GBP par value.

F2 · price: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Company's 2015 Incentive Award Plan (the 2015 Plan) and the 2015 Plan award agreement.

SEC source: 0001639691-25-000084 · wk-form4_1750193703.xml · derivative · entry 4

O'Kane Sharon · CIK 0001655980 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,042

Underlying: Ordinary Shares · 4,042 shares

Expires not disclosed

F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Company's 2025 Director Incentive Award Plan (the 2025 Plan) and the 2025 Plan award agreement.

F6 · derivative.exercise_date: The RSUs, granted under the 2025 Plan, vest on June 15, 2026, subject to continued service during the vesting period and the terms of the 2025 Plan award agreement.

F6 · derivative.expiration_date: The RSUs, granted under the 2025 Plan, vest on June 15, 2026, subject to continued service during the vesting period and the terms of the 2025 Plan award agreement.

SEC source: 0001639691-25-000084 · wk-form4_1750193703.xml · derivative · entry 3

O'Kane Sharon · CIK 0001655980 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 3,416 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Company's 2015 Incentive Award Plan (the 2015 Plan) and the 2015 Plan award agreement.

F4 · derivative.exercise_date: RSUs granted under the 2015 Plan on June 15, 2024 that vested on June 15, 2025.

F4 · derivative.expiration_date: RSUs granted under the 2015 Plan on June 15, 2024 that vested on June 15, 2025.

SEC source: 0001639691-25-000084 · wk-form4_1750193703.xml · nonDerivative · entry 2

O'Kane Sharon · CIK 0001655980 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,304

F3 · shares: Shares withheld to satisfy tax liability.

SEC source: 0001639691-25-000084 · wk-form4_1750193703.xml · nonDerivative · entry 1

O'Kane Sharon · CIK 0001655980 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,910

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Reporting person had vested restricted stock units (RSUs) settled in ordinary shares of LivaNova PLC (the Company), 1.00 GBP par value.

F2 · price: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Company's 2015 Incentive Award Plan (the 2015 Plan) and the 2015 Plan award agreement.

SEC source: 0001639691-25-000083 · wk-form4_1750193693.xml · derivative · entry 4

Bianchi Francesco · CIK 0001656080 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,042

Underlying: Ordinary Shares · 4,042 shares

Expires not disclosed

F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Company's 2025 Director Incentive Award Plan (the 2025 Plan) and the 2025 Plan award agreement.

F6 · derivative.exercise_date: The RSUs, granted under the 2025 Plan, vest on June 15, 2026, subject to continued service during the vesting period and the terms of the 2025 Plan award agreement.

F6 · derivative.expiration_date: The RSUs, granted under the 2025 Plan, vest on June 15, 2026, subject to continued service during the vesting period and the terms of the 2025 Plan award agreement.

SEC source: 0001639691-25-000083 · wk-form4_1750193693.xml · derivative · entry 3

Bianchi Francesco · CIK 0001656080 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 3,416 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Company's 2015 Incentive Award Plan (the 2015 Plan) and the 2015 Plan award agreement.

F4 · derivative.exercise_date: RSUs granted under the 2015 Plan on June 15, 2024 that vested on June 15, 2025.

F4 · derivative.expiration_date: RSUs granted under the 2015 Plan on June 15, 2024 that vested on June 15, 2025.

SEC source: 0001639691-25-000083 · wk-form4_1750193693.xml · nonDerivative · entry 2

Bianchi Francesco · CIK 0001656080 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,528

F3 · shares: Shares withheld to satisfy tax liability.

SEC source: 0001639691-25-000083 · wk-form4_1750193693.xml · nonDerivative · entry 1

Bianchi Francesco · CIK 0001656080 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,938

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Reporting person had vested restricted stock units (RSUs) settled in ordinary shares of LivaNova PLC (the Company), 1.00 GBP par value.

F2 · price: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Company's 2015 Incentive Award Plan (the 2015 Plan) and the 2015 Plan award agreement.

SEC source: 0001639691-25-000024 · wk-form4_1743555630.xml · derivative · entry 6

Kozmina Natalia · CIK 0002052336 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,986

Underlying: Ordinary Shares · 13,986 shares

Expires 2035-03-30

F7 · derivative.exercise_date: On March 30, 2025, reporting person was granted stock appreciation rights (SARs) subject to a four-year vesting in equal annual installments, the first vesting occurring on March 30, 2026. The SARs are subject to forfeiture prior to vesting in accordance with the terms of the Plan and the award agreement.

SEC source: 0001639691-25-000024 · wk-form4_1743555630.xml · derivative · entry 5

Kozmina Natalia · CIK 0002052336 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,388

Underlying: Ordinary Shares · 6,388 shares

Expires not disclosed

F3 · derivative.exercise_price: Each performance stock unit (PSU) represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Plan and the award agreement.

F6 · derivative.exercise_date: On March 30, 2025, reporting person was granted PSUs to vest or lapse on March 30, 2028 based on the Company's total shareholder return (TSR) for the three-year period beginning on January 1, 2025 and ending December 31, 2027 relative to the TSR of an index of companies, as determined by the Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement.

F6 · derivative.expiration_date: On March 30, 2025, reporting person was granted PSUs to vest or lapse on March 30, 2028 based on the Company's total shareholder return (TSR) for the three-year period beginning on January 1, 2025 and ending December 31, 2027 relative to the TSR of an index of companies, as determined by the Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement.

SEC source: 0001639691-25-000024 · wk-form4_1743555630.xml · derivative · entry 4

Kozmina Natalia · CIK 0002052336 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,194

Underlying: Ordinary Shares · 3,194 shares

Expires not disclosed

F3 · derivative.exercise_price: Each performance stock unit (PSU) represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Plan and the award agreement.

F5 · derivative.exercise_date: On March 30, 2025, reporting person was granted PSUs to vest or lapse on March 30, 2028 based on how the Company's Return on Investment Capital (ROIC) calculated for the performance period 2025-2027 compares to a target determined by the Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement.

F5 · derivative.expiration_date: On March 30, 2025, reporting person was granted PSUs to vest or lapse on March 30, 2028 based on how the Company's Return on Investment Capital (ROIC) calculated for the performance period 2025-2027 compares to a target determined by the Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement.

SEC source: 0001639691-25-000024 · wk-form4_1743555630.xml · derivative · entry 3

Kozmina Natalia · CIK 0002052336 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,194

Underlying: Ordinary Shares · 3,194 shares

Expires not disclosed

F3 · derivative.exercise_price: Each performance stock unit (PSU) represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Plan and the award agreement.

F4 · derivative.exercise_date: On March 30, 2025, reporting person was granted PSUs to vest or lapse on March 30, 2028 based on how the Company's free cash flow (FCF) for performance period 2025-2027 compares to a target determined by the Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement.

F4 · derivative.expiration_date: On March 30, 2025, reporting person was granted PSUs to vest or lapse on March 30, 2028 based on how the Company's free cash flow (FCF) for performance period 2025-2027 compares to a target determined by the Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement.

SEC source: 0001639691-25-000024 · wk-form4_1743555630.xml · derivative · entry 2

Kozmina Natalia · CIK 0002052336 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,388

Underlying: Ordinary Shares · 6,388 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the LivaNova PLC 2022 Incentive Award Plan (the Plan) and the award agreement.

F2 · derivative.exercise_date: On March 30, 2025, reporting person was granted RSUs subject to a three-year vesting in equal annual installments, the first vesting occurring on March 30, 2026. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the Plan and the award agreement.

F2 · derivative.expiration_date: On March 30, 2025, reporting person was granted RSUs subject to a three-year vesting in equal annual installments, the first vesting occurring on March 30, 2026. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the Plan and the award agreement.

SEC source: 0001639691-25-000024 · wk-form4_1743555630.xml · derivative · entry 1

Kozmina Natalia · CIK 0002052336 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,777

Underlying: Ordinary Shares · 12,777 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the LivaNova PLC 2022 Incentive Award Plan (the Plan) and the award agreement.

F2 · derivative.exercise_date: On March 30, 2025, reporting person was granted RSUs subject to a three-year vesting in equal annual installments, the first vesting occurring on March 30, 2026. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the Plan and the award agreement.

F2 · derivative.expiration_date: On March 30, 2025, reporting person was granted RSUs subject to a three-year vesting in equal annual installments, the first vesting occurring on March 30, 2026. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the Plan and the award agreement.

SEC source: 0001639691-25-000023 · wk-form4_1743555619.xml · derivative · entry 12

Poletti Franco · CIK 0002031281 · President, Cardiopulmonary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,986

Underlying: Ordinary Shares · 13,986 shares

Expires 2035-03-30

F13 · derivative.exercise_date: On March 30, 2025, reporting person was granted stock appreciation rights (SARs) subject to a four-year vesting in equal annual installments, the first vesting occurring on March 30, 2026. The SARs are subject to forfeiture prior to vesting in accordance with the terms of the 2022 Plan and the award agreement.

SEC source: 0001639691-25-000023 · wk-form4_1743555619.xml · derivative · entry 11

Poletti Franco · CIK 0002031281 · President, Cardiopulmonary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,388

Underlying: Ordinary Shares · 6,388 shares

Expires not disclosed

F9 · derivative.exercise_price: Each performance stock unit (PSU) represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the 2022 Plan and the award agreement.

F12 · derivative.exercise_date: On March 30, 2025, reporting person was granted PSUs to vest or lapse on March 30, 2028 based on the Company's total shareholder return (TSR) for the three-year period beginning on January 1, 2025 and ending December 31, 2027 relative to the TSR of an index of companies, as determined by the 2022 Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement.

F12 · derivative.expiration_date: On March 30, 2025, reporting person was granted PSUs to vest or lapse on March 30, 2028 based on the Company's total shareholder return (TSR) for the three-year period beginning on January 1, 2025 and ending December 31, 2027 relative to the TSR of an index of companies, as determined by the 2022 Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement.

SEC source: 0001639691-25-000023 · wk-form4_1743555619.xml · derivative · entry 10

Poletti Franco · CIK 0002031281 · President, Cardiopulmonary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,194

Underlying: Ordinary Shares · 3,194 shares

Expires not disclosed

F9 · derivative.exercise_price: Each performance stock unit (PSU) represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the 2022 Plan and the award agreement.

F11 · derivative.exercise_date: On March 30, 2025, reporting person was granted PSUs to vest or lapse on March 30, 2028 based on how the Company's Return on Investment Capital (ROIC) calculated for the performance period 2025-2027 compares to a target determined by the 2022 Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement.

F11 · derivative.expiration_date: On March 30, 2025, reporting person was granted PSUs to vest or lapse on March 30, 2028 based on how the Company's Return on Investment Capital (ROIC) calculated for the performance period 2025-2027 compares to a target determined by the 2022 Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement.

SEC source: 0001639691-25-000023 · wk-form4_1743555619.xml · derivative · entry 9

Poletti Franco · CIK 0002031281 · President, Cardiopulmonary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,194

Underlying: Ordinary Shares · 3,194 shares

Expires not disclosed

F9 · derivative.exercise_price: Each performance stock unit (PSU) represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the 2022 Plan and the award agreement.

F10 · derivative.exercise_date: On March 30, 2025, reporting person was granted PSUs to vest or lapse on March 30, 2028 based on how the Company's free cash flow (FCF) for performance period 2025-2027 compares to a target determined by the 2022 Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement.

F10 · derivative.expiration_date: On March 30, 2025, reporting person was granted PSUs to vest or lapse on March 30, 2028 based on how the Company's free cash flow (FCF) for performance period 2025-2027 compares to a target determined by the 2022 Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement.

SEC source: 0001639691-25-000023 · wk-form4_1743555619.xml · derivative · entry 8

Poletti Franco · CIK 0002031281 · President, Cardiopulmonary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,388

Underlying: Ordinary Shares · 6,388 shares

Expires not disclosed

F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Company's 2022 Incentive Award Plan (the 2022 Plan) and the award agreement.

F8 · derivative.exercise_date: On March 30, 2025, reporting person was granted RSUs subject to a three-year vesting in equal annual installments, the first vesting occurring on March 30, 2026. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the 2022 Plan and the award agreement.

F8 · derivative.expiration_date: On March 30, 2025, reporting person was granted RSUs subject to a three-year vesting in equal annual installments, the first vesting occurring on March 30, 2026. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the 2022 Plan and the award agreement.

SEC source: 0001639691-25-000023 · wk-form4_1743555619.xml · derivative · entry 7

Poletti Franco · CIK 0002031281 · President, Cardiopulmonary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,675

Underlying: Ordinary Shares · 559 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Company's 2022 Incentive Award Plan (the 2022 Plan) and the award agreement.

F7 · derivative.exercise_date: On March 30, 2024, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2025. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the 2022 Plan and the award agreement.

F7 · derivative.expiration_date: On March 30, 2024, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2025. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the 2022 Plan and the award agreement.

SEC source: 0001639691-25-000023 · wk-form4_1743555619.xml · derivative · entry 6

Poletti Franco · CIK 0002031281 · President, Cardiopulmonary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 650

Underlying: Ordinary Shares · 325 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Company's 2022 Incentive Award Plan (the 2022 Plan) and the award agreement.

F6 · derivative.exercise_date: On March 30, 2023, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2024. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the 2022 Plan and the award agreement.

F6 · derivative.expiration_date: On March 30, 2023, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2024. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the 2022 Plan and the award agreement.

SEC source: 0001639691-25-000023 · wk-form4_1743555619.xml · derivative · entry 5

Poletti Franco · CIK 0002031281 · President, Cardiopulmonary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 171

Underlying: Ordinary Shares · 172 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Company's 2015 Incentive Award Plan (the 2015 Plan) and the award agreement.

F4 · derivative.exercise_date: On March 30, 2022, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2023. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the 2015 Plan and the award agreement.

F4 · derivative.expiration_date: On March 30, 2022, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2023. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the 2015 Plan and the award agreement.

SEC source: 0001639691-25-000023 · wk-form4_1743555619.xml · derivative · entry 4

Poletti Franco · CIK 0002031281 · President, Cardiopulmonary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 201 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Company's 2015 Incentive Award Plan (the 2015 Plan) and the award agreement.

F3 · derivative.exercise_date: On March 30, 2021, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2022. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the 2015 Plan and the award agreement.

F3 · derivative.expiration_date: On March 30, 2021, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2022. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the 2015 Plan and the award agreement.

SEC source: 0001639691-25-000023 · wk-form4_1743555619.xml · nonDerivative · entry 2

Poletti Franco · CIK 0002031281 · President, Cardiopulmonary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,933

SEC source: 0001639691-25-000023 · wk-form4_1743555619.xml · nonDerivative · entry 1

Poletti Franco · CIK 0002031281 · President, Cardiopulmonary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,475

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Reporting person had vested restricted stock units (RSUs) settled in ordinary shares of LivaNova PLC (the Company), GBP 1.00 par value.

SEC source: 0001639691-25-000030 · wk-form4_1743555691.xml · derivative · entry 5

Tezel Ahmet · CIK 0002023439 · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,378

Underlying: Ordinary Shares · 22,378 shares

Expires 2035-03-30

F7 · derivative.exercise_date: On March 30, 2025, reporting person was granted stock appreciation rights (SARs) subject to a four-year vesting in equal annual installments, the first vesting occurring on March 30, 2026. The SARs are subject to forfeiture prior to vesting in accordance with the terms of the Plan and the award agreement.

SEC source: 0001639691-25-000030 · wk-form4_1743555691.xml · derivative · entry 4

Tezel Ahmet · CIK 0002023439 · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,222

Underlying: Ordinary Shares · 10,222 shares

Expires not disclosed

F3 · derivative.exercise_price: Each performance stock unit (PSU) represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Plan and the award agreement.

F6 · derivative.exercise_date: On March 30, 2025, reporting person was granted PSUs to vest or lapse on March 30, 2028 based on the Company's total shareholder return (TSR) for the three-year period beginning on January 1, 2025 and ending December 31, 2027 relative to the TSR of an index of companies, as determined by the Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement.

F6 · derivative.expiration_date: On March 30, 2025, reporting person was granted PSUs to vest or lapse on March 30, 2028 based on the Company's total shareholder return (TSR) for the three-year period beginning on January 1, 2025 and ending December 31, 2027 relative to the TSR of an index of companies, as determined by the Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement.

SEC source: 0001639691-25-000030 · wk-form4_1743555691.xml · derivative · entry 3

Tezel Ahmet · CIK 0002023439 · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,111

Underlying: Ordinary Shares · 5,111 shares

Expires not disclosed

F3 · derivative.exercise_price: Each performance stock unit (PSU) represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Plan and the award agreement.

F5 · derivative.exercise_date: On March 30, 2025, reporting person was granted PSUs to vest or lapse on March 30, 2028 based on how the Company's Return on Investment Capital (ROIC) calculated for the performance period 2025-2027 compares to a target determined by the Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement.

F5 · derivative.expiration_date: On March 30, 2025, reporting person was granted PSUs to vest or lapse on March 30, 2028 based on how the Company's Return on Investment Capital (ROIC) calculated for the performance period 2025-2027 compares to a target determined by the Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement.

SEC source: 0001639691-25-000030 · wk-form4_1743555691.xml · derivative · entry 2

Tezel Ahmet · CIK 0002023439 · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,111

Underlying: Ordinary Shares · 5,111 shares

Expires not disclosed

F3 · derivative.exercise_price: Each performance stock unit (PSU) represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Plan and the award agreement.

F4 · derivative.exercise_date: On March 30, 2025, reporting person was granted PSUs to vest or lapse on March 30, 2028 based on how the Company's free cash flow (FCF) for performance period 2025-2027 compares to a target determined by the Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement.

F4 · derivative.expiration_date: On March 30, 2025, reporting person was granted PSUs to vest or lapse on March 30, 2028 based on how the Company's free cash flow (FCF) for performance period 2025-2027 compares to a target determined by the Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement.

SEC source: 0001639691-25-000030 · wk-form4_1743555691.xml · derivative · entry 1

Tezel Ahmet · CIK 0002023439 · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,222

Underlying: Ordinary Shares · 10,222 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Company's 2022 Incentive Award Plan (the Plan) and the award agreement.

F2 · derivative.exercise_date: On March 30, 2025, reporting person was granted RSUs subject to a three-year vesting in equal annual installments, the first vesting occurring on March 30, 2026. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the Plan and the award agreement.

F2 · derivative.expiration_date: On March 30, 2025, reporting person was granted RSUs subject to a three-year vesting in equal annual installments, the first vesting occurring on March 30, 2026. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the Plan and the award agreement.

SEC source: 0001639691-25-000028 · wk-form4_1743555672.xml · derivative · entry 9

Makatsaria Vladimir · CIK 0002012645 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,927

Underlying: Ordinary Shares · 76,927 shares

Expires 2035-03-30

F10 · derivative.exercise_date: On March 30, 2025, reporting person was granted stock appreciation rights (SARs) subject to a four-year vesting in equal annual installments, the first vesting occurring on March 30, 2026. The SARs are subject to forfeiture prior to vesting in accordance with the terms of the Plan and the award agreement.

SEC source: 0001639691-25-000028 · wk-form4_1743555672.xml · derivative · entry 8

Makatsaria Vladimir · CIK 0002012645 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,139

Underlying: Ordinary Shares · 35,139 shares

Expires not disclosed

F6 · derivative.exercise_price: Each performance stock unit (PSU) represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Plan and the award agreement.

F9 · derivative.exercise_date: On March 30, 2025, reporting person was granted PSUs to vest or lapse on March 30, 2028 based on the Company's total shareholder return (TSR) for the three-year period beginning on January 1, 2025 and ending December 31, 2027 relative to the TSR of an index of companies, as determined by the Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement.

F9 · derivative.expiration_date: On March 30, 2025, reporting person was granted PSUs to vest or lapse on March 30, 2028 based on the Company's total shareholder return (TSR) for the three-year period beginning on January 1, 2025 and ending December 31, 2027 relative to the TSR of an index of companies, as determined by the Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement.

SEC source: 0001639691-25-000028 · wk-form4_1743555672.xml · derivative · entry 7

Makatsaria Vladimir · CIK 0002012645 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,569

Underlying: Ordinary Shares · 17,569 shares

Expires not disclosed

F6 · derivative.exercise_price: Each performance stock unit (PSU) represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Plan and the award agreement.

F8 · derivative.exercise_date: On March 30, 2025, reporting person was granted PSUs to vest or lapse on March 30, 2028 based on how the Company's Return on Investment Capital (ROIC) calculated for the performance period 2025-2027 compares to a target determined by the Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement.

F8 · derivative.expiration_date: On March 30, 2025, reporting person was granted PSUs to vest or lapse on March 30, 2028 based on how the Company's Return on Investment Capital (ROIC) calculated for the performance period 2025-2027 compares to a target determined by the Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement.

SEC source: 0001639691-25-000028 · wk-form4_1743555672.xml · derivative · entry 6

Makatsaria Vladimir · CIK 0002012645 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,569

Underlying: Ordinary Shares · 17,569 shares

Expires not disclosed

F6 · derivative.exercise_price: Each performance stock unit (PSU) represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Plan and the award agreement.

F7 · derivative.exercise_date: On March 30, 2025, reporting person was granted PSUs to vest or lapse on March 30, 2028 based on how the Company's free cash flow (FCF) for performance period 2025-2027 compares to a target determined by the Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement.

F7 · derivative.expiration_date: On March 30, 2025, reporting person was granted PSUs to vest or lapse on March 30, 2028 based on how the Company's free cash flow (FCF) for performance period 2025-2027 compares to a target determined by the Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement.

SEC source: 0001639691-25-000028 · wk-form4_1743555672.xml · derivative · entry 5

Makatsaria Vladimir · CIK 0002012645 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,139

Underlying: Ordinary Shares · 35,139 shares

Expires not disclosed

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Company's 2022 Incentive Award Plan (the Plan) and the award agreement.

F5 · derivative.exercise_date: On March 30, 2025, reporting person was granted RSUs subject to a three-year vesting in equal annual installments, the first vesting occurring on March 30, 2026. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the Plan and the award agreement.

F5 · derivative.expiration_date: On March 30, 2025, reporting person was granted RSUs subject to a three-year vesting in equal annual installments, the first vesting occurring on March 30, 2026. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the Plan and the award agreement.

SEC source: 0001639691-25-000028 · wk-form4_1743555672.xml · derivative · entry 4

Makatsaria Vladimir · CIK 0002012645 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,931

Underlying: Ordinary Shares · 5,978 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Company's 2022 Incentive Award Plan (the Plan) and the award agreement.

F4 · derivative.exercise_date: On March 30, 2024, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2025. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the Plan and the award agreement.

F4 · derivative.expiration_date: On March 30, 2024, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2025. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the Plan and the award agreement.

SEC source: 0001639691-25-000028 · wk-form4_1743555672.xml · derivative · entry 3

Makatsaria Vladimir · CIK 0002012645 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,055

Underlying: Ordinary Shares · 3,352 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Company's 2022 Incentive Award Plan (the Plan) and the award agreement.

F4 · derivative.exercise_date: On March 30, 2024, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2025. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the Plan and the award agreement.

F4 · derivative.expiration_date: On March 30, 2024, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2025. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the Plan and the award agreement.

SEC source: 0001639691-25-000028 · wk-form4_1743555672.xml · nonDerivative · entry 2

Makatsaria Vladimir · CIK 0002012645 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,284

F2 · shares: Shares withheld to satisfy tax liability.

SEC source: 0001639691-25-000028 · wk-form4_1743555672.xml · nonDerivative · entry 1

Makatsaria Vladimir · CIK 0002012645 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,330

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Reporting person had vested restricted stock units (RSUs) settled in ordinary shares of LivaNova PLC (the Company), GBP 1.00 par value.

SEC source: 0001639691-25-000029 · wk-form4_1743555682.xml · derivative · entry 14

Bolton Stephanie · CIK 0002012558 · President, Global Epilepsy

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,385

Underlying: Ordinary Shares · 15,385 shares

Expires 2035-03-30

F18 · derivative.exercise_date: On March 30, 2025, reporting person was granted stock appreciation rights (SARs) subject to a four-year vesting in equal annual installments, the first vesting occurring on March 30, 2026. The SARs are subject to forfeiture prior to vesting in accordance with the terms of the Plan and the award agreement.

SEC source: 0001639691-25-000029 · wk-form4_1743555682.xml · derivative · entry 13

Bolton Stephanie · CIK 0002012558 · President, Global Epilepsy

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,027

Underlying: Ordinary Shares · 7,027 shares

Expires not disclosed

F14 · derivative.exercise_price: Each PSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the 2022 Plan and the award agreement.

F17 · derivative.exercise_date: On March 30, 2025, reporting person was granted PSUs to vest or lapse on March 30, 2028 based on the Company's TSR for the three-year period beginning on January 1, 2025 and ending December 31, 2027 relative to the TSR of an index of companies, as determined by the 2022 Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement.

F17 · derivative.expiration_date: On March 30, 2025, reporting person was granted PSUs to vest or lapse on March 30, 2028 based on the Company's TSR for the three-year period beginning on January 1, 2025 and ending December 31, 2027 relative to the TSR of an index of companies, as determined by the 2022 Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement.

SEC source: 0001639691-25-000029 · wk-form4_1743555682.xml · derivative · entry 12

Bolton Stephanie · CIK 0002012558 · President, Global Epilepsy

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,513

Underlying: Ordinary Shares · 3,513 shares

Expires not disclosed

F14 · derivative.exercise_price: Each PSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the 2022 Plan and the award agreement.

F16 · derivative.exercise_date: On March 30, 2025, reporting person was granted PSUs to vest or lapse on March 30, 2028 based on how the Company's ROIC calculated for the performance period 2025-2027 compares to a target determined by the 2022 Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement.

F16 · derivative.expiration_date: On March 30, 2025, reporting person was granted PSUs to vest or lapse on March 30, 2028 based on how the Company's ROIC calculated for the performance period 2025-2027 compares to a target determined by the 2022 Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement.

SEC source: 0001639691-25-000029 · wk-form4_1743555682.xml · derivative · entry 11

Bolton Stephanie · CIK 0002012558 · President, Global Epilepsy

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,513

Underlying: Ordinary Shares · 3,513 shares

Expires not disclosed

F14 · derivative.exercise_price: Each PSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the 2022 Plan and the award agreement.

F15 · derivative.exercise_date: On March 30, 2025, reporting person was granted PSUs to vest or lapse on March 30, 2028 based on how the Company's FCF for performance period 2025-2027 compares to a target determined by the 2022 Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement.

F15 · derivative.expiration_date: On March 30, 2025, reporting person was granted PSUs to vest or lapse on March 30, 2028 based on how the Company's FCF for performance period 2025-2027 compares to a target determined by the 2022 Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement.

SEC source: 0001639691-25-000029 · wk-form4_1743555682.xml · derivative · entry 10

Bolton Stephanie · CIK 0002012558 · President, Global Epilepsy

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,027

Underlying: Ordinary Shares · 7,027 shares

Expires not disclosed

F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Company's 2022 Incentive Award Plan (the 2022 Plan) and the award agreement.

F13 · derivative.exercise_date: On March 30, 2025, reporting person was granted RSUs subject to a three-year vesting in equal annual installments, the first vesting occurring on March 30, 2026. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the 2022 Plan and the award agreement.

F13 · derivative.expiration_date: On March 30, 2025, reporting person was granted RSUs subject to a three-year vesting in equal annual installments, the first vesting occurring on March 30, 2026. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the 2022 Plan and the award agreement.

SEC source: 0001639691-25-000029 · wk-form4_1743555682.xml · derivative · entry 9

Bolton Stephanie · CIK 0002012558 · President, Global Epilepsy

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 1,060 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · derivative.exercise_price: Each PSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the 2015 Plan and the award agreement.

F12 · derivative.exercise_date: On March 30, 2022, reporting person was granted PSUs to vest or lapse on March 30, 2025 based on the Company's total shareholder return (TSR) for the three-year period beginning on January 1, 2022 and ending December 31, 2024 relative to the total shareholder return of a peer group of companies, as determined by the 2015 Plan Administrator. The Company's performance achieved a result of 58%, and the actual number of vested shares is presented as the quantity that was acquired.

F12 · derivative.expiration_date: On March 30, 2022, reporting person was granted PSUs to vest or lapse on March 30, 2025 based on the Company's total shareholder return (TSR) for the three-year period beginning on January 1, 2022 and ending December 31, 2024 relative to the total shareholder return of a peer group of companies, as determined by the 2015 Plan Administrator. The Company's performance achieved a result of 58%, and the actual number of vested shares is presented as the quantity that was acquired.

SEC source: 0001639691-25-000029 · wk-form4_1743555682.xml · derivative · entry 8

Bolton Stephanie · CIK 0002012558 · President, Global Epilepsy

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 717 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · derivative.exercise_price: Each PSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the 2015 Plan and the award agreement.

F11 · derivative.exercise_date: On March 30, 2022, reporting person was granted PSUs to vest or lapse on March 30, 2025 based on the Company's Return on Investment Capital (ROIC) for performance period 2022-2024 compared to a target determined by the 2015 Plan Administrator. The performance achieved was 78.5%, and the actual number of vested shares is presented as the quantity that was acquired.

F11 · derivative.expiration_date: On March 30, 2022, reporting person was granted PSUs to vest or lapse on March 30, 2025 based on the Company's Return on Investment Capital (ROIC) for performance period 2022-2024 compared to a target determined by the 2015 Plan Administrator. The performance achieved was 78.5%, and the actual number of vested shares is presented as the quantity that was acquired.